Dopamine Formation Competitors

At Revolution Medicines, we aim to change the trajectory of disease for patients living with RAS-addicted cancers around the world. We challenge assumptions, act on what the science reveals, and push beyond convention to tackle some of the most difficult-to-treat cancers. Our differentiated, platform-driven approach targets RAS in its active, ON state—unlocking a fundamentally new way to inhibit RAS. We are advancing a broad, integrated pipeline of inhibitors with the ambition to establish RAS(ON) inhibition as the backbone for treating RAS-addicted cancers while continuing to pioneer the next generation of innovation. We follow the science and act on it with urgency to turn insights into new treatments—because for patients, the stakes are deeply personal, measured in time and quality of life.

Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won’t stop until all of the cells’ secrets are revealed.

bluebird bio has rebranded as Genetix Biotherapeutics, returning to our foundational roots and renewing our commitment to delivering transformative genetic therapies for patients living with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. Follow our new page at the link below!